Profound to Showcase TULSA-PRO(TM), the TULSA Procedure(TM) and the Future of iMRI at AUA2026

The most recent release on 2026-05-14 announces that Profound Medical will feature four oral presentations at the AUA2026 Annual Meeting, focusing on real-world data and clinical outcomes for the TULSA Procedure. The company also disclosed a new strategic initiative to explore integrating PSMA PET molecular imaging with the TULSA Procedure to improve treatment planning and patient monitoring. The exploration is at an early stage – integrating PSMA PET into the TULSA-PRO treatment planning software – and is positioned as a future enhancement to physician precision. The news is primarily a conference showcase and a nod to future product development, with no new commercial or financial data.

This release is incremental and expected. Over the past six months, the company has delivered genuinely material news: the CAPTAIN trial’s primary safety endpoint success (March 13, 2026), Humana becoming the first national U.S. payer to cover the TULSA Procedure, and a 104% year-over-year revenue surge in Q1 2026 with full-year revenue guidance of $25 million. In that context, a conference presence and an early-stage exploration of PSMA PET integration does not alter the investment thesis. The market has already priced in a significant growth trajectory following the CAPTAIN data and reimbursement wins; this release adds no new financial or clinical catalysts. It confirms the company’s ongoing R&D direction, but it is not a material event, nor does it change the risk/reward profile. The rating “Material – Pending 122B” (from the JSON metadata) appears to be an internal placeholder, not a reflection of actual market-moving content. The transcript states management expects coverage decisions from private insurers in H2 2026 and finalizes compatibility with Siemens’ new MR system by late 2026. None of that is accelerated by this announcement. Therefore, the impact is positive but routine.

Profound Medical is a commercial-stage medical device company focused on AI‑powered, MRI‑guided, incision-free therapies. Its flagship product, TULSA‑PRO, uses robotically controlled transurethral ultrasound with real‑time MRI thermography to ablate prostate tissue (cancer and BPH) while preserving urinary and sexual function. The TULSA Procedure is cleared in the U.S., Europe, Canada, and several other markets. A secondary platform, Sonalleve, treats uterine fibroids and adenomyosis using similar MRI‑guided ablation, primarily sold outside the U.S. The company’s strategy centers on expanding the TULSA‑PRO installed base, driving recurring revenue through procedure disposables, and achieving positive cash flow at ~$85 million annual revenue.